1. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study. (December 2018) Authors: Namikawa, Kenjiro; Kiyohara, Yoshio; Takenouchi, Tatsuya; Uhara, Hisashi; Uchi, Hiroshi; Yoshikawa, Shusuke; Takatsuka, Sumiko; Koga, Hiroshi; Wada, Naoko; Minami, Hironobu; Hatsumichi, Masahiro; Asada, Suguru; Namba, Yoshinobu; Yamazaki, Naoya Journal: European journal of cancer Issue: Volume 105(2018) Page Start: 114 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. (August 2019) Authors: Ueno, Makoto; Ikeda, Masafumi; Morizane, Chigusa; Kobayashi, Satoshi; Ohno, Izumi; Kondo, Shunsuke; Okano, Naohiro; Kimura, Keisuke; Asada, Suguru; Namba, Yoshinobu; Okusaka, Takuji; Furuse, Junji Journal: Lancet gastroenterology and hepatology Issue: Volume 4:Number 8(2019) Page Start: 611 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗